Hope to Thyroid Patients is Given

Hope is a very powerful thing indeed. In fact, hope is so powerful that when you are facing a powerful disease that is threatening your life, hope is what keeps you going so that you can one day defeat this plague attacking you and live your life again to the fullest. Oncotarget is a peer-reviewed journal that has made it their mission to show the link between hope and the defeat of cancer. While they openly acknowledge that hope alone cannot defeat this disease, they have shown quite strongly on why hope increases the patient’s quality of life, overall satisfaction, and ultimately, aids in treatment. In other words, if a patient has hope they are more likely to win the battle against cancer. Follow Oncotarget on Twitter.

Oncotarget recently brought great hope to those who suffer from papillary thyroid carcinoma. Patients diagnosed with papillary thyroid carcinoma lose hope from the onset. This is because oncologist tell them that one day papillary thyroid carcinoma will become resistant to the drug vemurafenib since their cancer is based on the mutated BRAF gene. The only hope to defeat papillary thyroid carcinoma is to allow the cancer to go into remission and hope it never comes back. Should the cancer come out of remission, the patient is doomed. However, Oncotarget recently interviewed Dr. Carmelo Nucero has brought wonderful news to those who suffer from thyroid cancer. Follow Oncotarget on Linkedin.

On their weekly podcast, which you can get on iTunes, Oncotarget allowed Dr. Carmelo Nucero to discuss his research.

Dr. Carmelo Nucero found that if you mix vemurafenib with another drug, you might be able to trick the body so that it stops attacking vemurafenib and instead attacks another. There were many failed attempts in this regard. However, Dr. Carmelo Nucero finally discovered that if you combined vemurafenib with palbociclib, then extraordinary results would happen.

These two drugs work together to induce stronger cancer cell death and also promote healthier cell regeneration. Since both the drugs are FDA approved this seems that very soon people with papillary thyroid carcinoma will have hope to defeat their cancer that comes out of remission.

Listen: https://www.stitcher.com/podcast/oncotarget

Leave a Reply

Your email address will not be published. Required fields are marked *